EU begins real-time review of Sanofi/GlaxoSmithKline vaccine; U.S. states sit on a surplus of millions of doses; Relmada Therapeutics spends $15 million for Arbormentis’ psychedelics.
Five things for health marketers to know: Tuesday, April 6, 2021
U.S. administering an average of 3.1 million COVID-19 vaccine doses per day; FDA rejects Acadia application to expand use of anti-psychosis drug; Johnson & Johnson bets $780 million on flu antiviral conjugate therapies.
Five things for pharma marketers to know: Monday, April 5, 2021
Bristol-Myers Squibb pays $75 million in Medicaid settlement; Pfizer builds sterile injectables plant in Michigan; scientists say it’s still unknown whether vaccinated people can carry the COVID-19 virus.
Five things for health marketers to know: Friday, April 2, 2021
IRS alleges Bristol Myers Squibb avoided $1.4 billion in taxes; Advisory committee members urge FDA to reject Biogen Alzheimer’s drug; Biden administration rolls out first vaccine confidence TV spots.
Five things for health marketers to know: Thursday, April 1, 2021
Pfizer vaccine proves effective in adolescents; COVID-19 ranks as third leading cause of death in 2020; Former Merck exec set to lead Generate Biomedicines.
Five things for health marketers to know: Wednesday, March 31, 2021
Pfizer to test vaccine version that doesn’t require cold storage; Vaccine hesitancy rates drop; Biden administration to create volunteer network to boost vaccine confidence.
Five things for health marketers to know: Tuesday, March 30, 2021
Nursing homes struggle to vaccinate employees; FDA approves BMS/Bluebird CAR-T therapy Abecma; Biden administration plans to double the number of pharmacy vax sites.
Five things for health marketers to know: Monday, March 29, 2021
Rutgers to require all students to vaccinate for fall classes; Gyroscope Therapeutics wins $148 million Series C for dry-AMD gene therapy; Amazon rolls out vaccination sites for frontline employees.
Five things for health marketers to know: Friday, March 26, 2021
Biden doubles vaccine goal to 200 million doses within his first 100 days; Pfizer starts testing COVID-19 vaccine in young children; Bristol Myers Squibb data on LAG-3 class shows promise in melanoma treatment.
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix